Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference

NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the Stifel 2021 Virtual Healthcare Conference, taking place November 15-17, 2021. Stifel 2021 Virtual Healthcare Conference Presentation Date:Wednesday, November 17th, 2021Time: 2:00pm Eastern TimeWebcast: The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com About Immunovant, Inc.  Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401 (batoclimab), a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.  Contact: Tom Dorney, MS, MBADirector, Investor Relations & StrategyImmunovant, [email protected]